Agilent expands RNA portfolio

PALO ALTO, Calif.—Agilent Technologies announced it has acquired Boulder, Colo.-based SynPro Corp., which manufactures short nucleic acid molecules for use by the biopharmaceutical industry. It has also hired the existing staff of 22. The acquisition provides Agilent with a value-added opportunity for its existing platforms that support this industry. According to company estimates, the current nucleic acids synthesis market is approximately $700 million, with an estimated growth potential of 10 to 20 percent per year.